Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Prostatype Genomics

0.15 SEK-3.21 %21.9. klo 12.30
Less than 1K followers

PROGEN

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-3.21 %
+31.30 %
-38.18 %
-56.48 %
+32.29 %
-38.94 %
-99.24 %
-99.94 %
-99.89 %

Prostatype Genomics operates in the medical technology sector. The company specializes in the development of medical genetic tests used for the identification, analysis and further follow-up of prostate cancer. In addition to its main business, related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic market. The head office is located in Nacka Strand.

Read more
Market cap
84.57M SEK
Turnover
331.84K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
11.2.
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release17.09.2026 klo 18.20

Prostatype Genomics AB receives approximately SEK 12.5 million through the exercise of warrants of series TO6

Prostatype Genomics
Regulatory press release10.09.2026 klo 13.00

The last day of trading in Prostatype Genomics AB’s warrants of series TO6 is tomorrow

Prostatype Genomics
Regulatory press release01.09.2026 klo 09.45

The exercise period for warrants of series TO6 starts today

Prostatype Genomics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release31.08.2026 klo 11.40

Prostatype Genomics receives commitments and letters of intent of approx. 70 percent of the exercise of warrants TO6

Prostatype Genomics
Regulatory press release31.08.2026 klo 10.30

Prostatype Genomics publishes its interim report for the first half of 2026

Prostatype Genomics
Regulatory press release05.08.2026 klo 21.30

Prostatype Genomics AB resolves on a directed issue

Prostatype Genomics
Regulatory press release03.08.2026 klo 17.30

Prostatype Genomics AB announces last day of trading in BTUs and first day of trading in warrants of series TO6 and TO7

Prostatype Genomics
Regulatory press release27.07.2026 klo 19.00

Prostatype Genomics AB announces outcome in rights issue of units

Prostatype Genomics
Regulatory press release21.07.2026 klo 09.00

Last day for subscription in Prostatype Genomics AB's rights issue of units is July 23, 2026

Prostatype Genomics
Regulatory press release09.07.2026 klo 09.30

The subscription period in Prostatype Genomics AB's rights issue of units begins today

Prostatype Genomics
Regulatory press release08.07.2026 klo 21.45

Prostatype Genomics AB publishes information memorandum prior to rights issue of units

Prostatype Genomics
Regulatory press release08.07.2026 klo 20.45

Prostatype Genomics AB enters into top-down underwriting ahead of upcoming rights issue of units

Prostatype Genomics
Regulatory press release29.06.2026 klo 21.00

The Board of Directors of Prostatype Genomics AB resolves on the previously announced rights issue of units of approximately SEK 47.4 million

Prostatype Genomics
Regulatory press release22.06.2026 klo 19.45

Bulletin from annual general meeting in Prostatype Genomics AB (publ)

Prostatype Genomics
Regulatory press release01.06.2026 klo 11.45

Prostatype Genomics publishes Annual Report for 2025

Prostatype Genomics
Regulatory press release25.05.2026 klo 09.45

Update from Prostatype Genomics Regarding the Medicare Reimbursement Process for Prostatype® in the United States

Prostatype Genomics
Regulatory press release19.05.2026 klo 23.00

NOTICE OF ANNUAL GENERAL MEETING IN PROSTATYPE GENOMICS AB (PUBL)

Prostatype Genomics
Regulatory press release19.05.2026 klo 22.50

Prostatype Genomics AB announces the Board of Directors’ intention to resolve on a rights issue of units of approximately SEK 47.4 million

Prostatype Genomics
Regulatory press release26.02.2026 klo 17.45

Prostatype Genomics publishes year-end report for 2025

Prostatype Genomics
Regulatory press release12.01.2026 klo 09.55

Loan financing of SEK 10 million to Prostatype Genomics AB

Prostatype Genomics